BRCA1 and ovarian carcinoma: The PARPi, olaparib, has shown efficacy in both the relapsed setting, in women with BRCA1/2 mutations and ovarian cancer [19], and when used as maintenance therapy in women with sporadic high grade serous ovarian cancer, improving progression-free survival time, when compared to placebo [20].